MDS experts, Dr Alan List and Dr David Sallman, explain that the goals of therapy for patients with higher-risk myelodysplastic syndromes (MDS) are to improve symptoms, decrease the risk of leukemia, and improve survival. The primary treatment options for higher-risk MDS discussed are: hypomethylating agents (azacitidine and decitabine) and allogeneic stem cell transplant.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.